OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NUTM55

Nutrition Profess PCL

PharmaceuticalsVerified

Nutrition Profess PCL maintains a capital structure with 120 million shares outstanding, both basic and diluted, indicating no immediate dilution pressure from share-based compensation or convertible instruments. The company reported free cash flow of 29,926,210 THB, suggesting it generates sufficient cash to support operations and potentially fund growth initiatives. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability is reflected in a gross profit of 253,247,900 THB and an operating income of 25,731,130 THB. While these figures indicate a healthy gross margin, the operating margin is relatively low at 8.57%, which is below the typical range for pharmaceutical and health product companies. This suggests that the company may face cost pressures or pricing constraints in its operations. Nutrition Profess PCL operates in a single business segment focused on nutritional supplements and health products. The company's revenue is concentrated in this segment, with no disclosed geographic diversification. This concentration may expose the company to regional economic or regulatory risks, particularly in Thailand, where it is headquartered. The company's growth trajectory is not clearly defined in the available data. No forward-looking revenue guidance or historical growth rates are provided, making it difficult to assess the company's future performance. The absence of capital expenditure data beyond a small negative value of -624,570 THB suggests limited investment in new projects or expansion. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. Additionally, the company's reliance on a single business segment and geographic concentration may increase its vulnerability to market fluctuations. There is no indication of dilution pressure in the near term, as shares outstanding remain unchanged between basic and diluted counts. Recent events and filings are not detailed in the available data. The company's 10-K or equivalent disclosures are not accessible in the provided source documents, limiting the ability to analyze recent strategic moves or financial developments.

30-day price · NUTM(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyNutrition Profess PCL
TickerNUTM.BK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Nutrition Profess PCL is a Thai company that develops, produces, and distributes nutritional supplements and health products, primarily targeting the consumer staples and healthcare markets.

Classification. Nutrition Profess PCL is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Nutrition Profess PCL maintains a capital structure with 120 million shares outstanding, both basic and diluted, indicating no immediate dilution pressure from share-based compensation or convertible instruments. The company reported free cash flow of 29,926,210 THB, suggesting it generates sufficient cash to support operations and potentially fund growth initiatives. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability is reflected in a gross profit of 253,247,900 THB and an operating income of 25,731,130 THB. While these figures indicate a healthy gross margin, the operating margin is relatively low at 8.57%, which is below the typical range for pharmaceutical and health product companies. This suggests that the company may face cost pressures or pricing constraints in its operations. Nutrition Profess PCL operates in a single business segment focused on nutritional supplements and health products. The company's revenue is concentrated in this segment, with no disclosed geographic diversification. This concentration may expose the company to regional economic or regulatory risks, particularly in Thailand, where it is headquartered. The company's growth trajectory is not clearly defined in the available data. No forward-looking revenue guidance or historical growth rates are provided, making it difficult to assess the company's future performance. The absence of capital expenditure data beyond a small negative value of -624,570 THB suggests limited investment in new projects or expansion. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. Additionally, the company's reliance on a single business segment and geographic concentration may increase its vulnerability to market fluctuations. There is no indication of dilution pressure in the near term, as shares outstanding remain unchanged between basic and diluted counts. Recent events and filings are not detailed in the available data. The company's 10-K or equivalent disclosures are not accessible in the provided source documents, limiting the ability to analyze recent strategic moves or financial developments.
Key takeaways
  • Nutrition Profess PCL generates strong gross profits but has a low operating margin, indicating potential cost or pricing pressures.
  • The company's capital structure shows no immediate dilution risk, with basic and diluted shares outstanding being equal.
  • Free cash flow is positive, suggesting the company can support operations and potentially fund growth.
  • The company's business is concentrated in a single segment and geographic region, increasing exposure to local market risks.
  • Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$300.2M
Gross profit$253.2M
Operating income$25.7M
Net income$19.9M
R&D
SG&A
D&A
SBC
Operating cash flow$40.2M
CapEx-$624.6k
Free cash flow$29.9M
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$922.7M$88.0M$75.2M$44.6M
FY-3$859.4M$47.3M$39.8M$62.8M
FY-2$1.18B$84.4M$65.1M$97.9M
FY-1$1.16B$71.5M$55.2M$92.9M
FY0$1.03B$73.7M$58.2M$956.0k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$473.9M$223.9M$31.8M
FY-3$493.8M$265.4M$83.3M
FY-2$498.8M$299.0M$124.2M
FY-1$495.2M$279.7M$149.3M
FY0$689.7M$495.5M$372.7M
PeriodOCFCapExFCFSBC
FY-4$86.7M-$51.8M$44.6M
FY-3$100.9M-$13.5M$62.8M
FY-2$123.7M-$9.5M$97.9M
FY-1$134.0M-$6.2M$92.9M
FY0$110.5M-$14.0M$956.0k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$300.2M$25.7M$19.9M$29.9M
FQ-6$272.8M$9.8M$7.7M$18.1M
FQ-5$279.8M$17.0M$13.6M$22.7M
FQ-4$308.1M$19.0M$14.0M$22.2M
FQ-3$290.0M$35.8M$28.9M$35.3M
FQ-2$239.5M$17.7M$14.9M$24.5M
FQ-1$244.7M$11.8M$8.5M-$25.2M
FQ0$258.2M$8.3M$6.0M$12.0M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3$480.5M$262.9M$142.1M
FQ-2$704.3M$523.0M$384.2M
FQ-1$685.0M$489.5M$358.9M
FQ0$689.7M$495.5M$372.7M
PeriodOCFCapExFCFSBC
FQ-7$40.2M-$624.6k$29.9M
FQ-6$61.0M-$1.2M$18.1M
FQ-5$84.0M-$3.3M$22.7M
FQ-4$134.0M-$6.2M$22.2M
FQ-3$49.9M-$4.2M$35.3M
FQ-2$56.7M-$5.6M$24.5M
FQ-1$83.2M-$8.6M-$25.2M
FQ0$110.5M-$14.0M$12.0M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion2.0%
CapEx/Revenue-0.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricNUTMActivity
Op margin8.6%7.7% medp25 -2.4% · p75 15.5%above median
Net margin6.6%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin84.4%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-0.2%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity25.0% medp25 3.8% · p75 63.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-02 04:15 UTC#28ff4be3
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 19:29 UTCJob: bdd70a50